Pharmaceutical company AbbVie (NYSE: ABBV) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.

Is now the time to buy ABBV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales growth from Skyrizi and Rinvoq, as well as double-digit expansion in neuroscience products, as key contributors to the performance. However, despite surpassing Wall Street revenue and profit estimates, the market reacted negatively, reflecting heightened concern over a sharp drop in operating margin and the persistence of headwinds in the aesthetics segment. CEO Rob Michael acknowledged challenging economic conditions affecting discretionary spending and emphasized the company’s execution in core therapeutic areas.

Looking ahead, AbbVie’s revised guidance reflects management’s acknowledgment of ongoing pressures, with a cautious tone around margin recovery and uncertainty in aesthetics demand. The company is focused on driving growth through new product launches and expanding indications, particularly within immunology and neuroscience. Management remains confident in the long-term potential of its pipeline, highlighting upcoming milestones such as regulatory submissions for tavapadon in Parkinson’s disease and label expansions for Rinvoq and Skyrizi. CFO Scott Reents noted, “We are increasing R&D investments to support a broad pipeline, positioning AbbVie for sustainable growth into the next decade.”

Key Insights from Management’s Remarks

AbbVie’s leadership attributed third quarter performance to robust immunology and neuroscience sales and highlighted pipeline progress amid lingering margin pressures and softer aesthetics demand.

• Immunology engine outperformed: Skyrizi and Rinvoq delivered over 40% combined sales growth, with notable upticks in Crohn’s disease and ulcerative colitis, capturing significant share among patients switching therapies.
• Neuroscience momentum: Double-digit growth in neuroscience was led by migraine treatments (Qulipta, Ubrelvy), Vraylar for bipolar disorder, and the Parkinson’s franchise, where VYALEV exceeded expectations internationally.
• Aesthetics faces macro headwinds: The aesthetics portfolio, including Botox and Juvederm, saw operational declines due to weak consumer sentiment and reduced discretionary spending, particularly in the U.S.
• Pipeline advancement: Management highlighted progress on 90+ programs, including positive Phase III results for Rinvoq in alopecia areata and vitiligo, regulatory submissions for tavapadon in Parkinson’s, and pivotal oncology data for Temab-A.
• Strategic investments and deals: Recent acquisitions (Capstan Therapeutics, Gilgamesh) expanded exposure to in vivo CAR-T immunology platforms and next-generation psychiatric therapies, supporting AbbVie’s stated intent to invest heavily in R&D.

Drivers of Future Performance

AbbVie’s forward outlook is shaped by sustained immunology and neuroscience growth, R&D investment, and ongoing pressure in aesthetics and operating margins.

• Immunology and neuroscience as growth pillars: Management expects Skyrizi and Rinvoq to remain central to top-line expansion, with label extensions and new market entries planned. Neuroscience products, notably VYALEV and tavapadon, are positioned to boost revenue as coverage and adoption increase.
• Margin recovery and R&D spend: The company aims for margin stabilization by leveraging operational efficiencies and SG&A discipline, but margin headwinds from higher R&D expenditure and lingering acquired R&D charges will persist in the near term.
• Aesthetics and macro uncertainty: AbbVie anticipates continued softness in aesthetics due to inflation-sensitive consumer behavior and global market challenges, while new consumer campaigns and product launches are expected to drive eventual recovery, though timing remains uncertain.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will be monitoring (1) the pace of label expansions and regulatory milestones for Rinvoq, Skyrizi, and tavapadon; (2) stabilization and potential rebound in aesthetics demand as new consumer campaigns and product launches roll out; and (3) the impact of recent pipeline acquisitions and R&D investments on clinical progress and future revenue streams. Execution on these fronts, alongside margin recovery efforts, will be key to AbbVie’s trajectory.

AbbVie currently trades at $218.21, down from $228.08 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free for active Edge members).

High Quality Stocks for All Market Conditions

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.